With Dr. Marjorie G. Zauderer, Memorial Sloan Kettering Cancer Center and Dr. John Bomalaski, Polaris Pharmaceuticals.
This program is open and appropriate for medical professionals as well as patients, their families, and anyone else interested in learning more.
Study Summary:
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma has been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
